Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $55.00.

SLN has been the subject of a number of research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, March 2nd. Jefferies Financial Group raised shares of Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, March 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Tuesday, April 21st.

Silence Therapeutics Trading Down 4.1%

NASDAQ SLN opened at $6.71 on Wednesday. Silence Therapeutics has a 52 week low of $4.19 and a 52 week high of $8.40. The stock has a market cap of $316.98 million, a price-to-earnings ratio of -4.22 and a beta of 1.48. The company has a 50-day moving average price of $6.74 and a two-hundred day moving average price of $6.10.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). The company had revenue of $0.42 million during the quarter, compared to analyst estimates of $1.26 million. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. As a group, equities research analysts expect that Silence Therapeutics will post -0.95 earnings per share for the current fiscal year.

Institutional Trading of Silence Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC boosted its holdings in Silence Therapeutics by 48.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after buying an additional 500,000 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Silence Therapeutics by 121.0% in the 4th quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock worth $4,010,000 after acquiring an additional 361,080 shares during the last quarter. Ishara Investments LP acquired a new position in shares of Silence Therapeutics in the 4th quarter worth $1,459,000. ADAR1 Capital Management LLC grew its holdings in shares of Silence Therapeutics by 628.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock worth $907,000 after acquiring an additional 148,514 shares during the last quarter. Finally, Seven Fleet Capital Management LP acquired a new position in shares of Silence Therapeutics in the 4th quarter worth $897,000. 98.73% of the stock is owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.